CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed ...

When it comes to weight loss, providers and patients argue that GLP-1 medications are not a one-for-one swap and that volatile insurance coverage contradicts the science and experience of people ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Ginger also understands what it means to be a visible figure in the body-diverse community. Should she win All Stars 10, ...